Dr. Reddy’s Q4 Results 2025: Net Profit Jumps 22%, Revenue Up 20%; Announces 800% Dividend, 1:5 Stock Split

Dr Reddy's Laboratories, one of India's top pharmaceutical firms, released its performance results for the March quarter of financial year 2025 (Q4 FY2025) on Friday, May 9. The company posted a 22% year-on-year (YoY) rise in its consolidated net profit, reaching Rs 1,594 crore, exceeding market analysts' expectations of Rs1,491 crore. Revenue also outperformed predictions, rising to Rs 8,506 crore, a growth of 20% from Rs 7,083 crore in the same quarter last year.

Dr Reddy Q4 Results 2025 Live:

Dr Reddy Q4 EBITDA and Margins: On the operating side, Dr. Reddy's EBITDA reached Rs 2,975 crore, marking a significant 58.9% increase from Rs 1,872 crore in Q4. Margins expanded by 510 basis points, reaching 29.1%, compared to 24% in the same quarter of the previous fiscal year.

Co-Chairman and Managing Director (MD) of Dr Reddy Laboratories, G.V. Prasad announced, "We achieved double-digit growth across our businesses, driven by successful product launches, increased revenues from key products in the U.S., and the integration of the acquired NRT business. We will continue to focus on strengthening our core businesses through portfolio management and operational excellence, while exploring strategic partnerships and inorganic growth opportunities."

Dr Reddy's Laboratories Earnings Call: Segment-Wise Performance in Q4

Breaking down the segment-wise performance, revenue from Global Generics, which constitutes nearly 90% of the company's total revenue, stood at Rs 7,536 crore, compared to Rs 6,119 crore in the previous year. Revenue from Pharmaceutical Services and Active Ingredients amounted to Rs 1,167 crore in Q4FY25, compared to Rs 1,152 crore last year, as stated in the company's Q4 earnings filing.

Dr Reddy's Dividend 2025 and 1:5 Stock Split: Pharma Stock's 800% Dividend

Along with announcing its Q4 results, the pharmaceutical company declared an 800% dividend for shareholders, amounting to Rs 8 per share with a face value of Rs 1. This follows the company's share split in a 1:5 ratio in October of the previous year. To determine the eligible shareholders, Dr Reddy's Lab has also set the record date.

The company said, "The record date for purpose of determining the members eligible to receive the final dividend for the financial year ended March 31, 2025, has been fixed as July 10, 2025."